Research: Opioids, Surgery & Cognitive Decline in Aging

For older adults undergoing surgery, the procedure itself may be only part of the challenge. A growing body of research points to a troubling complication known as postoperative cognitive dysfunction (POCD) — a persistent decline in memory and cognitive performance that can linger long after the operating room. A 2026 study published in Brain, Behavior, and Immunity by Muscat, Deems, Alvarez, and colleagues now offers one of the most detailed mechanistic pictures yet of why this happens — and, critically, what might be done about it. The findings center on an unexpected culprit: disrupted mitochondrial function deep within the hippocampus, the brain's primary memory center.

What This Study Found

Using an aged rat model designed to simulate the clinical reality of surgery combined with perioperative opioid (morphine) administration, researchers systematically investigated the biological pathways underlying long-term memory deficits. The results, according to the study, were striking in their specificity.

First, the researchers found that memory impairments observed in surgery-plus-morphine animals were not explained by systemic illness or broad dendritic degeneration — the kind of widespread neurological damage one might assume. Instead, the damage was highly selective. Animals treated with surgery and morphine showed reductions in specific dendritic spine subtypes associated with synaptic stability. These are the microscopic structures that allow neurons to communicate with one another, and their selective loss suggests targeted disruption of memory-forming circuitry.

Compounding this, the study found impaired late-phase long-term potentiation (LTP) — a cellular mechanism considered essential to forming lasting memories — alongside a blunted ability to upregulate GluA1, a key subunit of the AMPA receptor involved in synaptic strengthening. Together, these synaptic abnormalities paint a picture of a hippocampus that has lost its ability to adapt and encode new information effectively.

Importantly, the researchers also detected elevated levels of neurofilament light chain (Nf-L) in circulation — a biomarker associated with axonal injury — suggesting that nerve fiber damage was ongoing and sustained, not merely an acute response to surgical trauma.

Perhaps the most significant finding involved mitochondrial function. Surgery and morphine-treated animals exhibited persistent hippocampal mitochondrial dysfunction characterized by impaired oxidative phosphorylation, reduced respiratory reserve capacity, and increased DNA oxidation. Critically, these mitochondrial deficits were not observed in liver tissue, arguing against a body-wide energy crisis and instead pointing to a brain-specific vulnerability in the context of aging and opioid exposure.

The study then examined two potential therapeutic strategies. First, pharmacological inhibition of central TLR4 signaling — a key driver of neuroinflammation — at the time of surgery was found to attenuate oxidative stress and partially restore mitochondrial function, implicating early inflammatory cascades in the development of long-term mitochondrial damage. Second, and perhaps most clinically provocative, administration of SS-31 — a mitochondria-targeted peptide — four weeks after surgery robustly rescued hippocampal-dependent memory and normalized mitochondrial respiratory function. Notably, this benefit occurred even though DNA oxidation and Nf-L levels remained persistently elevated, suggesting that restoring mitochondrial energy production may be sufficient to recover functional memory even in the presence of residual molecular damage.

Clinical Significance

POCD is not a rare or minor concern. It disproportionately affects older surgical patients and can manifest as difficulties with concentration, memory, and processing speed that persist for weeks, months, or even years following surgery. For aging populations who frequently undergo procedures for orthopedic, cardiac, or cancer-related conditions, the cognitive cost of surgery may be substantial and underappreciated.

This study suggests that opioids used in perioperative pain management may be a significant contributing factor to this cognitive burden — not simply the surgery itself. The researchers' identification of hippocampal mitochondrial dysfunction as a central mechanistic substrate opens a potentially important new avenue for both prevention and treatment.

The finding that neuroinflammatory signaling via TLR4 appears to initiate the cascade leading to mitochondrial impairment suggests that the window for early intervention — perhaps at or around the time of surgery — could be clinically meaningful. Meanwhile, the demonstration that mitochondrial-targeted peptides like SS-31 can rescue memory function even weeks after the insult suggests that late therapeutic intervention may also be viable, offering hope for patients who are already experiencing cognitive decline following surgery.

It must be emphasized that this research was conducted in aged rats, and human clinical data will be necessary to determine whether these findings translate to human physiology and clinical outcomes. Nonetheless, the mechanistic precision of these results provides a compelling scientific rationale for future investigation.

Current Access and Compliance Context

SS-31 (also known as elamipretide) is a mitochondria-targeting peptide that has been the subject of ongoing research across multiple domains, including heart failure, neurodegenerative conditions, and aging-related mitochondrial decline. It is not currently approved by the FDA as a therapeutic agent for any indication in the United States and remains under active clinical investigation.

Peptides like SS-31 are increasingly discussed in the context of longevity research and cognitive health, but individuals should be aware that access, formulation quality, and appropriate clinical supervision vary widely. The landscape of peptide therapeutics requires careful navigation, and compounding pharmacies, research-use designations, and evolving regulatory frameworks all play a role in how these agents can be accessed.

For anyone considering peptide-based interventions — particularly in the context of cognitive health, aging, or surgical recovery — working with a qualified, knowledgeable physician is essential. Self-administration without medical oversight carries meaningful risks, including issues of dosing, purity, and contraindications.

What Patients Should Know

If you or a loved one is planning a surgical procedure and are concerned about postoperative cognitive changes, this research — while still at the preclinical stage — offers several important takeaways worth discussing with your healthcare provider:

• Age matters: The study specifically used an aged rat model, reflecting the clinical reality that older individuals are most vulnerable to POCD. This is a conversation worth initiating before surgery, not after.
• Opioid use is a variable: The study suggests that perioperative opioid administration contributes independently to cognitive outcomes. Discussing opioid-sparing anesthetic strategies with your surgical team may be worthwhile.
• Mitochondrial health is emerging as a relevant factor: While no approved mitochondrial therapies exist specifically for POCD, the growing research base in mitochondrial medicine is encouraging and worth monitoring.
• Early neuroinflammation may set the stage: The identification of TLR4-mediated neuroinflammation as an upstream driver suggests that anti-inflammatory strategies around the time of surgery could have long-term cognitive implications — an area ripe for clinical investigation.
• Human studies are needed: As with all preclinical research, these findings must be replicated and validated in human trials before clinical recommendations can be made.

Conclusion

The 2026 study by Muscat and colleagues represents a meaningful step forward in understanding why so many older surgical patients experience lasting cognitive difficulties — and, more encouragingly, suggests that these deficits may not be inevitable or irreversible. By identifying sustained hippocampal mitochondrial dysfunction as a key mechanistic driver of opioid-associated POCD, and demonstrating that mitochondrial-targeted peptide therapy can rescue memory function in an aged animal model, this research highlights mitochondrial bioenergetics as a promising and potentially actionable therapeutic frontier.

If you are interested in learning more about peptide-based research in aging and cognitive health, or would like to find a physician who is knowledgeable about the current evidence landscape, we encourage you to visit peptideassociation.org/find-a-doctor to connect with a qualified provider in your area.

---

Medical Disclaimer: This article is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. The research discussed is based on preclinical animal studies, and findings may not directly translate to human outcomes. Always consult a licensed and qualified healthcare professional before making any decisions regarding medications, peptides, surgical planning, or cognitive health interventions.

---

Citation: Muscat SM, Deems NP, Alvarez BD, et al. Disruption of hippocampal mitochondrial function underlies opioid-induced postoperative cognitive dysfunction in aged rats. Brain Behav Immun. 2026;(August). doi:10.1016/j.bbi.2026.106942. PMID: 42546889.